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Abnormal blood brain barrier (BBB) permeability has been implicated in the 
neuropathogenesis of chronic HIV infection. As neurocognitive impairment can persist 
despite effective combination antiretroviral therapy (cART), it is possible that irreversible 
central nervous system (CNS) processes are initiated in early infection, before cART is 
typically initiated. We analyzed the natural history of BBB permeability in primary HIV 
infection (PHI), and the effects of cART initiated during this period. CSF:Serum albumin 
quotient (QAlb), a marker of BBB permeability, was measured in longitudinal 
observational studies of PHI. We analyzed trajectories of QAlb pre- and post-cART using 
mixed-effects models, and associations between QAlb and CSF neurofilament light chain 
(NFL), NAA:Cr, a magnetic resonance spectroscopy N-acetylaspartate:creatinine (
biomarker for neuronal integrity), and neuropsychological testing. Age-adjusted QAlb was 
elevated in PHI vs. controls at baseline (n=106, median 91 days post infection, dpi; n=64; 
p=0.02). Before cART, QAlb increased over time in 84 participants with normal baseline 
QAlb (p=0.006), and decreased in 22 with high baseline QAlb (p=0.011). QAlb correlated at 
baseline and longitudinally with NFL (r=0.497, p<0.001; r=0.555, p<0.001) and NAA:Cr 
in parietal grey matter (r=-0.352, p=0.015, r=-0.387, p=0.008), but not 
neuropsychological performance. QAlb did not change after a median 398 days of cART 
initiated at 225 dpi (p=0.174). QAlb rises during early HIV, associates with neuronal 
injury, and does not significantly improve over a year of treatment. HIV BBB-associated 
neuropathogenesis may be initiated in early infection. 
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As of 2016, the CDC reports more than 1.2 million individuals are living with human 
immunodeficiency virus (HIV) in the United States, with as many as 1 in 8 unaware of 
their diagnosis1,2. HIV has significant genetic diversity, exhibiting different strains, 
subtypes, and even sub-subtypes, internationally. HIV-1 is the most predominant form 
worldwide, apart from western Africa3, and will be the focus of this thesis. Herein, 'HIV' 
refers to HIV-1.  
 
Neurocognitive dysfunction in HIV 
I. HIV-associated neurocognitive disorder (HAND) 
HIV infection can have significant systemic ramifications, and the central nervous system 
(CNS) is no exception. Chronic exposure to HIV can frequently lead to devastating 
neurological complications, with approximately one third of untreated patients 
developing HIV associated dementia (HAD) 4. HAD is characterized by severe cognitive, 
motor, and behavioral disturbances associated with global cerebral atrophy, with 
subcortical areas exhibiting particular susceptibility 5. Given the morbidity of the illness 
in the absence of treatment, HAD is considered an AIDS-defining illness, with disease 
severity correlating with the degree of CD4+ suppression6,7. With the introduction of 
highly active antiretroviral therapy (HAART)/combination antiretroviral therapy (cART) 
in 1995, and thus restoration of CD4+ counts and effective viral load suppression, the 
incidence of HAD has significantly decreased to as low as 5%8,9. However, a milder 
spectrum of neurocognitive deficits persists despite successful cART treatment, effecting 
up to 50% of chronically infected patients8-10. HIV-associated neurocognitive disorders 
(HAND) is an umbrella term for this observed spectrum of neurocognitive complications, 
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comprised of three categories: asymptomatic neurocognitive impairment (ANI), mild 
neurocognitive disorder (MND), and HAD, in increasing severity4,11.  
 As indicated above, HAND predominantly involves the subcortical region and 
frontostriatal circuits, often manifesting as cortical atrophy and white matter signal 
hyperintensities detectable on magnetic resonance imaging (MRI)12, although these 
findings are neither specific nor sensitive13,14. Corresponding to the imaging findings, the 
cognitive domains most commonly affected include motor, psychological (agitation, 
apathy, depression), executive, speed of processing information, and attention, with very 
limited involvement of language, judgment, and reasoning12,15. Like any form of 
dementia, HAND is a clinical diagnosis, and the above domains may be assessed 
clinically with a battery of neuropsychological testing (ie, trail making, grooved 
pegboard), which allows for classification in one of the HAND categories. All categories 
of HAND require impairment in at least 2 tested domains, while the degree of 
impairment in functional performance determines the category: no impairment qualifies 
as ANI, mild impairment qualifies as MND, and moderate-to-severe impairment qualifies 
as HAD16. Undoubtedly, these neurocognitive deficits, even when mild, can have a 
severe impact on the patient's quality of life, and may even compromise cART adherence, 
resulting in viral resistance and disease progression17. Thus, the continued foothold of 
HAND in post-cART era is an issue necessitating better understanding and further 
investigation.  
II. Neuropathogenesis in HAND  
Since the mid-1980s, numerous autopsy studies have characterized the histological 
hallmarks of HAD with relative consensus: If HAD is the clinical manifestation of severe 
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neurocognitive deficits, HIV-encephalitis (HIVE) is the pathologic correlate. Apart from 
gross evidence of diffuse brain atrophy--indicative of neuronal loss--and correspondingly 
enlarged ventricles, tissue specimens in classic HAD demonstrate wide-spread 
inflammation. This characteristic inflammation, termed HIVE, is defined by the presence 
of activated resident macrophages (ie, microglia) and infiltrating peripheral macrophages, 
with specific findings as follows: multinucleated giant cells expressing viral antigens like 
p24 (likely representing viral fusion of macrophages), activated microglial nodules, 
perivascular 'cuffs' (leukocyte aggregation in the perivascular space), marked astrocytosis 
(astrocyte activation and dysfunction)18, white matter gliosis and demyelination, synapto-
dendritic injury, and the presence of detectable virus production19-23.  
 Even in the post-cART era, post-mortem analysis of patients with mild forms of 
HAND surprisingly still shows marked neuroinflammation24. Although pathologically 
similar to HIVE, productive HIV infection is not detectable, and the structural sites of 
inflammation are different, now primarily involving the hippocampus and surrounding 
peri-entorhinal cortex with less involvement of the basal ganglia6. While some argue that 
the milder forms of HAND in the post-cART era may represent a different pathological 
process from pre-cART HAD, it is clear that neuroinflammation likely contributes to 
pathogenesis in both. In fact, the degree of histologic neuroinflammation correlates 
strongly with clinical progression of HAND6; in 1995, Glass et al showed a strong 
correlation between neurologic disease progression and macrophage staining, whereas 
HIV-1 staining (ie, gp41 expression) demonstrated a weak correlation at best25. These 
findings by Glass, and similar pathologic and experimental findings by other researchers 
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in years to come, implicated inflammation as a key player in HIV-mediated 
neurodegeneration, more so than viral load.  
 Neuronal toxicity is thought to be primarily due to indirect mechanisms, such as 
inflammation, as repeated histological and in vitro studies have shown HIV to have very 
limited, if any, infection of neurons.  Few post-mortem PCR studies have shown that HIV 
has the capability to invade neurons26,27, although the infected proportion is small (as 
neurons do not express required HIV receptors) and the infection is likely nonproductive 
(as neurons cannot regenerate)28. Although this putative neuronal infection is thought to 
have an inconsequential role in neuropathogenesis, replication-derived viral proteins can 
exert neurotoxic effects either directly via apoptotic activation or indirectly via induction 
of inflammatory cytokines: Tat (transcriptional transactivator), gp120 (envelope 
glycoprotein), and VPR (viral protein R) have been most strongly implicated in HIV-
mediated neurodegeneration, stimulating apoptosis through activation of caspase-3 or -8, 
and up-regulating microglial synthesis of IL-1β and TNF-α6,19,20,28,29. Thus, HIV is 
thought to cause neuronal injury via induction of a pro-inflammatory state, but also via 
secretion of neurotoxic viral proteins, with a strong interplay and synergistic effect 
between these two mechanisms. Notably, excito-toxicity is thought to be the common 
endpoint of both pathways, as inflammatory cytokines and HIV-encoded proteins have 
been shown to increase extracellular glutamate concentration in the CNS, resulting in 
excess activation of the N-methyl-d-aspartate (NMDA) receptor, and subsequent 
apoptosis20,30,31. (For a discussion on how HIV breaches the BBB and induces 
neuroinflammation, see section titled "Role of the blood brain barrier" below.) 
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III. Theories underlying persistence of HAND despite successful cART  
As indicated in the above sections, even in the context of successful cART therapy (ie, 
undetectable viral load on ultrasensitive tests), HAND persists in milder forms. Several 
explanations have been offered, although the answer is still unclear. A few theories will 
be discussed briefly below.  
 One possibility is the presence of continued low-grade neuroinflammation even 
with complete viral suppression, as suggested by the autopsy studies of Tavazzi et al 
demonstrating marked neuroinflammation without histologic signs of viral replication 
(referenced above in "Neuropathogenesis of HAND"). It is speculated that resolution of 
inflammation in the CNS is slower than the periphery32, and may remain unchecked for 
years, with persistently abnormal inflammatory biomarkers9.  
 A second possibility is continued low-grade viral replication in the CNS. As an 
immune privileged site, the brain may serve as a perfect viral sanctuary for HIV to escape 
exposure to cART circulating in the periphery33. cART penetration into the CNS is 
limited, even in regimens with a high 'CNS Penetration Effectiveness' (see "cART therapy 
overview" below), thus allowing for continued CNS replication even with viral 
eradication in the periphery9. Persistence of HIV in the CNS may also allow for evolution 
of drug-resistant strains, as the presence of genetically distinct populations in the CSF 
versus the plasma has been well documented in chronic infection19,34. 
 A third possibility is the confounding effect of comorbidities prevalent in HIV+ 
patients35; although the resulting neurocognitive diseases are histologically distinct from 
HAND, they may be difficult to distinguish clinically. Such confounders include medical 
comorbidities (ie, cardiovascular disease, co-infection with hepatitis)36-41, psychological 
disease (ie, depression)42-44, drug abuse (ie, crack/cocaine)41,45, medication-related side 
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effects, and increased susceptibility to age-related neurodegenerative processes (ie, 
acceleration of amyloid-driven diseases such as Alzheimer's and Parkinson's)6,46-51. In 
regards to medication-related side effects, ART therapy is known to cause neurotoxicity, 
the severity of which may correlate with CNS Penetration Effectiveness6,44,52.  
 Perhaps most relevant to the purpose of this thesis, the fourth possibility is that 
this persisting neurocognitive impairment may represent irreversible neuronal damage 
accrued prior to the initiation of cART, even in early infection53. Thus, investigative 
efforts have been drawn towards elucidating and characterizing the earliest stages of HIV 
neuroinvasion and associated neuronal injury, as will be explored further below.  
 
Initiation of neuropathogenesis in early HIV infection  
 
Primary HIV infection (PHI) refers to the earliest stage of systemic infection, from time 
of transmission up to 12 months post-transmission, encompassing the time of 
seroconversion and establishment of virus load set point54. An acute retroviral syndrome 
(ARS) develops in over half of PHI patients, and is thought to represent either a direct 
cytotoxic effect or immunologic response to the high load viremia typical of the acute 
phase of infection. Clinical symptoms of ARS tend to be nonspecific, classically a 
mononucleosis- or influenza-like syndrome which can last several days to weeks; 
however, neurological symptoms, such as aseptic meningitis, encephalitis, or 
radiculopathy, develop in up to 17% during seroconversion, and may be associated with a 
more rapid progression of neurocognitive deficits55,56. Several studies have demonstrated 
HIV infiltration of the CNS during PHI57-59, as indicated by the presence of HIV RNA in 
the CSF compartment, as early as eight days post-infection, even preceding the 
manifestation of neurological symptoms 4,59-62. CNS immune activation accompanies this 
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viral invasion as reflected by elevations of CSF white blood count, the soluble CSF 
biomarkers neopterin (reflecting macrophage activation) and CXCL-10/IP-10 (a 
lymphocyte chemokine), and T lymphocyte activation in CSF4,63-66. Furthermore, markers 
of immune activation may reflect degree of viral load and neurocognitive impairment67.  
 Accumulating evidence suggests that this pro-inflammatory state coincides with 
neuronal damage during PHI. Neurofilament light chain (NFL) is one of three subunits 
which comprises the cytoskeletal protein neurofilament, an intermediate filament 
essential for axonal support of myelinated neurons. It is an established CSF biomarker of 
axonal damage in a variety of neurological processes, with growing prominence in HIV-
related neurodegeneration. The reason for this trend is that, unlike other CSF biomarkers 
which are reflective of viral load or immune activation, NFL directly reflects the severity 
of active neuronal damage32. Elevations in NFL have also been demonstrated in PHI, 
even in neuroasymptomatic patients, indicative of subclinical injury50,68.  
 Another useful method of detecting neuronal damage and CNS inflammation 
utilizes magnetic resonance spectroscopy (MRS), a noninvasive quantitative MR 
technique which measures alterations in cerebral metabolite levels. Previous MRS studies 
have shown elevation of inflammatory cerebral metabolites in acute HIV (prior to 
antibody seroconversion) which increases longitudinally over time in PHI prior to 
cART4,69,70, as well as elevation in neuronal injury metabolites responsive to ART 69. The 
cerebral metabolite N-acetylaspartate (NAA) is a marker of neuronal viability and 
number, and is often expressed as a value normalized to creatinine (NAA:Cr). We have 
previously shown a strong correlation between high NFL and low NAA:Cr in the parietal 
grey matter of neurosymptomatic PHI subjects 68. Thus, crucial processes during the 
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primary phase of viral infection may underlie the initiation of HIV associated CNS 
injury. 
 Whether clinically overt signs of neurocognitive impairment begin in PHI is not 
clear, as studies have been limited.  A meta-analysis has previously concluded that 
cognitive deficits in early HIV infection are rare and mild15, although several primary 
studies have been published since then, either noting deficits in a large subgroup71,72, or 
finding no deficits73,74. Notably, these studies varied in the timing of their analysis 
relative to date of transmission, a relevant point if the earlier phases of infection are 
dominated by sub-clinical neuronal injury.  
 
Role of the blood brain barrier 
I. Anatomy of the blood brain barrier  
The highly restrictive blood brain barrier (BBB) defines almost the entirety of the brain's 
capillary endothelium, bestowing the CNS with a specialized microenvironment distinct 
from systemic circulation75. These endothelial cells are tightly opposed via junctional 
protein complexes, called zonulae occludentes, which prevents any paracellular 
passage76. Other components of the neurovascular unit (NVU) include peri-endothelial 
cells, specifically pericytes and astrocytes; the NVU also interacts with the resident CNS 
immune cells, called microglia77,78(Figure 1). The ratio of albumin in the cerebrospinal 
fluid to albumin in the serum (CSF:serum albumin concentration quotient, or QAlb) is a 
specific marker for BBB permeability79. Albumin is synthesized exclusively in the liver 
and is largely excluded from the CSF. Upon deregulation of the neurovascular unit and 
sequential loss of tight junctions, BBB permeability to albumin increases, resulting in an 
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increased QAlb. Some researchers caution against using QAlb as a blood-brain barrier 
marker and state that it actually reflects the permeability of the blood-CSF barrier at the 
choroid plexus80, since the choroid vasculature is more prone to inflammation and 
'leakiness' compared to the intraparenchymal vasculature. But in cases of stroke, which 
leaves the choroid plexus intact and injures the cerebrovascular endothelial cells, QAlb  is 
increased81, suggesting that QAlb is a marker of both barriers.  
 
Figure 1. Key players of the blood brain barrier are shown. Endothelial cells are conjoined by tight 
junctional proteins, the expression of which are affected by ligand-receptor interactions. Pericytes closely 
encircle the endothelial cells within the basal lamina, while astrocyte endfeet provide support just outside 
of the basal lamina. The resident central nervous system macrophages, microglia, interact with the 
neurovascular unit within the perivascular space. Adapted with permission from Abbott NJ et al. (2006) 
Astrocyte–endothelial interactions at the blood–brain barrier, Nature Reviews Neuroscience. 7: 41–53.  
 Expression of the endothelial junctional proteins, such as occludin-1 and ZO-1, 
and the viability of endothelial cells are highly influenced by environmental factors, 
including expression of pro-inflammatory cytokines such as TNF-α and IL-1β 48,82,83, 
direct infection by various neurotropic viruses39,84, or exposure to cytotoxic molecules in 
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the serum85. All three of these factors are thought to be involved in the pathogenesis of 
HAND (See "Neuropathogenesis in HAND" above). Is it possible that the BBB, the 
guardian of the CNS so susceptible to environmental factors, is implicated in the neuro-
pathogenesis of HAND?   
II. Dysregulation of the blood brain barrier in HIV  
In order to exert its neurological effects, HIV and/or its viral products must first traverse 
the BBB. Although the mechanisms have not yet been fully clarified, several models 
have been proposed. The aptly named "Trojan horse theory" is perhaps the most widely 
accepted, suggesting the HIV virus crosses the BBB primarily via infection of peripheral 
monocytes destined to take up residence in the CNS as macrophages 20. Although this 
model indicates that HIV is able to traverse the largely intact BBB, increased 
permeability of the BBB has been strongly implicated in the progression of HIV 
neurological dysfunction68,86-89. Since the early 1990s, studies have shown that QAlb is 
increased in infected individuals90,91 and is strongly associated with the presence of 
neurological signs/symptoms92. Around this time, post-mortem studies of chronically 
infected AIDS patients provided tissue evidence of the correlation between BBB 
dysregulation and neurological impairment, as serum protein deposition in subcortical 
white matter was greater in those with neurological symptoms89. Peluso and colleagues 
reported a significant correlation between the axonal injury marker NFL and QAlb, further 
suggesting a possible relationship between a dysregulated BBB and neurological 
dysfunction68. In line with this observation, several studies have shown that the neuronal 
injury accrued upon CNS infiltration is not a direct result of cytolytic infection61,88. On 
the contrary, within the CNS, HIV infection is restricted to macrophages, microglia, and, 
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to a lesser extent, endothelial and peri-endothelial cells of the neurovascular unit (ie, 
astrocytes and pericytes) which compromise the BBB85,93. As will be discussed below, it 
is the downstream effects of HIV infection in these cells that will culminate in neuronal 
injury through a compromised BBB.  
 It is speculated that increased BBB permeability is a critical contributor to HIV 
neuropathogenesis as disruption of this regulatory interface facilitates CNS infiltration of 
potentially harmful substances from the periphery, resulting in compounding viral entry 
and susceptibility to the inflammatory assault of immune cells88. Gisslén and colleagues 
demonstrated a significant relationship between QAlb, CSF HIV-1 RNA, and the 
macrophage activation marker neopterin, thus suggesting a strong association between 
immune activation as an important factor in BBB permeability in HIV infection87. In line 
with this theory, monocyte infiltration has previously been found to correlate with loss of 
tight junction immunoreactivity in brain tissue of HAD patients94. Similar to the 
speculated mechanisms of neuropathogenesis outlined previously (See 
"Neuropathogenesis in HAND" above), growing evidence suggests BBB permeability is 
the result of a multifactorial process involving immune-mediated mechanisms, as well as 
viral mechanisms. For example, the HIV-1 derived proteins Tat and gp120 exhibit direct 
neurotoxic effects, but also severely compromise the integrity of the BBB, permitting the 
entry of peripheral cytokines and additional infected monocytes and free virions 20. 
Furthermore, infection of pericytes, which encircle and stabilize endothelial cells of the 
BBB, has been shown to diminish tight junction integrity and increase permeability in 
vitro93. Even in the presence of low HIV infection, astrocytes undergo altered end feet 
signaling, accelerating endothelial apoptosis95. The inflammatory cascade that results 
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from entry of peripheral cytokines and immune cells, further exacerbated by activation of 
residential CNS macrophages and microglial cells, results in a storm of reactive oxygen 
species, nitric oxide, glutamate, cytokines, and other neurotoxins that ultimately lead to 
neuronal damage and death20. Interestingly, it should be noted that albumin itself 
produces concentration-dependent neurotoxic effects in rat brain parenchyma in vivo96, 
and induces expression of the pro-inflammmatory cytokines IL-1β and TNF-α possibly 
via MAP-K activation in astrocytes and microglial cells97-99. Thus, it may be these 
resident immune cells rather than infiltrating macrophages are the cause of neuro-
inflammation and neuro-toxicity once the BBB is compromised.  
 Although BBB dysregulation is thought to be secondary to viral and immune-
mediated processes directly related to HIV-infection, one must not discount the influence 
of HIV-related comorbidities. Concurrent infections may significantly alter BBB, either 
via direct NVU infection or induction of cytokines which indirectly cause BBB hyper-
permeability. Most notably, up to one third of HIV-infected patients are concurrently 
infected with Hepatitis C, which directly infects NVU endothelial cells and may cause 
neurocognitive dysfunction37. Drug abuse is highly prevalent in HIV+ populations, with 
cocaine and methamphetamine implicated in BBB dysruption38. Cardiovascular disease is 
also commonly accelerated in HIV+ patients due to chronic systemic inflammation and 
metabolic side effects of cART therapy (ie, protease inhibitors)35,100,101. Given the 
presence of cardiovascular disease and its risk factors (hypertension, 
hypercholesterolemia) have been associated with neurocognitive decline in HIV36, it 
likely contributes to BBB hyper-permeability.  
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III. Blood brain barrier status in early HIV infection 
As indicated above, dysregulation of the BBB is a well-established event in chronic HIV 
infection and correlates with neurological injury and neuro-inflammation. However there 
is very limited data assessing blood brain barrier integrity during the primary phase of 
infection. Moderate elevations of albumin ratio in PHI have previously been shown in 
cross-sectional studies 50,60, and there exists a strong association between matrix 
metalloproteinases--enzymatic surrogate markers of BBB permeability--and 
neurocognitive status in early HIV102. Although studies assessing BBB status in PHI 
patients are limited, several studies have analyzed albumin ratio in neuro-asymptomatic 
patients (recruited regardless of chronicity/transmission date), often with mixed results, 
either demonstrating increased QAlb compared to uninfected controls60,87 or no significant 
difference32,103.  
 
Role of cART therapy  
I. cART therapy overview  
Since clinical trials with azidothymidine (AZT) in 1987, it has been known that 
antiretroviral therapy can significantly reverse HAD, as assessed by clinical 
neuropsychological testing and positron emission tomography104. This improvement is 
clearly enhanced with highly antiretroviral therapy (HAART)/combination ART 
(cART)10,105, the standard of treatment for HIV. There are 24 FDA-approved ARTs 
currently available with varying molecular actions: (1) nucleoside-analog reverse 
transcriptase inhibitors (NRTIs), (2) non-nucleoside reverse transcriptase inhibitors 
(NNRTIs), (3) protease inhibitors (PI), (4) integrase inhibitors, (5) fusion inhibitors, and 
(6) co-receptor antagonists. Drugs from at least two different molecular classes are 
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combined in a cART regimen (consisting of three or more drugs), with the underlying 
purpose of preventing drug resistance106. Most commonly, regimens consist of two 
NRTIs with one PI or one NNRTI. Nevertheless, cART regimens are highly 
heterogeneous and may require complex, specific regimens necessitating as many as 30 
pills a day17, though many patients are able to take single pill regimens in the modern era.  
 While certain regimens have a higher 'CNS Penetration Effectiveness' (CPE)107, 
and thus better ability to cross the BBB and control CSF viral load, studies regarding the 
clinical impact of CPE have been mixed52, primarily demonstrating unchanged or 
worsened neuropsychological performance associated with these regimens108,109. Apart 
from inherent bias involved in these study designs (ie, patients with more severe HAD 
are prescribed a higher CPE regimen)34, there are other possible explanations. Not only 
are high CPE drugs intuitively more likely to be neurotoxic, but some researchers argue 
that the pathology of HAND is inflammation-mediated and not viral load-dependent (see 
above sections), as the viral load may simply reflect plasma spillover from a leaky 
BBB110. As cART medications directly target viral load and not the activated 
inflammatory cascade, neuropsychological damage may persist with the continued low-
grade inflammation. Thus, as no specific cART regimen is considered superior for the 
treatment of HAND16, individual regimens are based on the consideration of several 
factors (ie, regimen complexity and compliance, CPE, drug-resistance testing). 
II. Effects of cART therapy on neuropathogenesis in early infection  
Given the remarkable and indisputable effect of cART on HAD, more recent studies have 
aimed to assess cognitive benefits from earlier initiation of cART. In a longitudinal 
observational study of PHI patients, cART therapy was shown to attenuate, although not 
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fully reverse, abnormalities in MRS metabolite markers69. Although it was speculated 
that normalization may occur beyond the limited follow-up period (median of 6.0 
months), persistent neuroinflammation is known to occur despite successful cART (see 
"Theories underlying persistence of HAND despite successful cART" above). Of note, 
MRS markers of excitotoxicity exhibited greater attenuation than markers of 
inflammation, perhaps suggesting persistent low-grade inflammation without significant 
neurotoxicity. A similarly designed study assessed MRS abnormalities, but this time in 
acute HIV infection (recruited within one month of transmission versus one year in PHI), 
and found normalization with cART therapy70; thus, it may be that reversibility is 
achieved with earlier cART initiation. Effects of cART on neuropsychological 
performance in early infection have also been examined, although limited to two 
studies71,72. The PHI study identified mild deficits with at least a partial response to 
cART therapy; the second study, this time in acute HIV infection, demonstrated no 
measurable neurocognitive deficits in the majority of patients, although a subgroup with 
severe deficits showed very limited response to cART.  The above studies suggest that 
neuropathogenesis may have varied response to cART, as dictated by a combination of 
factors, including timing of cART initiation and the severity of neurologic disease.   
III. Effect of cART therapy on the blood brain barrier  
Surprisingly, the effect of cART therapy on BBB permeability has not been intensely 
evaluated. In an unpublished study, Crozier and colleagues reported the gradual 
diminishment of albumin ratio from a median baseline of 6.48 to a median endpoint value 
of 6.09 in 16 neuroasymptomatic patients with chronic HIV infection after 200 days of 
cART therapy111; thus, although BBB integrity improved over time with cART therapy, a 
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return to premorbid or near premorbid function may take years. In contrast, Abdulle and 
colleagues observed no significant reduction in BBB permeability after 2 years of cART 
treatment in 38 neuroasymptomatic patients32. Importantly, the median baseline albumin 
ratio of patients in the Crozier study was higher (6.48, range: 4.79-10.29,) than that of 
patients in the Abdulle study (4.45, range: 1.77-9.84), potentially contributing to the 
discrepancy in cohort response to cART. No studies have investigated the effect of cART 
therapy on BBB permeability in early stages of infection. 
 
 STATEMENT OF PURPOSE 
 
In this study, we aimed to elucidate the natural history of BBB permeability during PHI, 
and to determine whether these changes, if any, were associated with biomarkers of 
neuropathogenesis. Additionally, we sought to determine whether BBB permeability was 
responsive to cART treatment initiated during early HIV infection. Our specific study 
questions and accompanying aims are delineated below:  
I. What is the natural history of blood brain barrier permeability during primary 
HIV infection? 
• Aim: To determine the longitudinal trajectory of blood brain barrier 
permeability, as measured by QAlb, in primary HIV infection, in the 
absence of cART treatment.  
II. Is blood brain barrier status associated with neuropathogenesis during primary 
infection?  
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• Aim: To determine whether QAlb correlates with markers of neuronal 
injury (NFL), neuronal health (NAA:Cr), and neuropsychological testing 
(NPZ).  
III. Does early combination antiretroviral treatment (cART) influence QAlb?   
• Aim: To determine whether cART initiation effects the slope of the 
QAlb trajectory established in Aim I, and associated markers of 
neuropathogenesis in Aim II.  
 We hypothesized that a) QAlb will increase over time for cART-naive patients, and 
b) QAlb will correlate positively with markers for neuronal injury (NFL), and inversely 
with neuropsychological test performance (NPZ) and neuronal health (NAA:Cr). 
Furthermore, c) following initiation of effective cART regimen, as indicated by reduced 
CSF HIV-1 RNA, we expect QAlb to gradually diminish with improvement in 
aforementioned markers of early CNS injury/inflammation.   
These results will provide novel understanding of the changes to the brain 
microenvironment that begin during initial HIV infection, and the persistence of these 





Individuals with PHI were recruited into prospective longitudinal studies of CNS HIV in 
Gothenburg, Sweden, and San Francisco, USA, between 1986 and 2014, as previously 
described 60 and outlined below. Participants were within the first year of HIV 
transmission as confirmed by the standard serologic testing algorithm for recent HIV 
seroconversion (STAHRS) 112, and all but three were ART-naive. A subset began cART 
  18   
 
at variable times during follow up for reasons outside of the study. None of the 
participants had a prior neurological disease history. A history of substance abuse was not 
an exclusion criterion, but no participants reported same-day substance abuse, which 
would have led to censoring of data.  Date of HIV transmission was approximated as 14 
days prior to the onset of seroconversion symptoms, when present 113; otherwise, it was 
approximated as midway between the dates of the last negative and first positive EIA 
test114.  HIV-uninfected volunteers were recruited from the San Francisco community, 




The study protocol was approved by the institutional review board of each institution 
involved. All study participants gave written consent.  
 
Data collection and laboratory analysis 
 
Paired CSF and blood/plasma samples were obtained and neuropsychological testing and 
MRS were performed at each visit as described in detail below42,68.  Study intervals were 
scheduled at baseline (t=0), six weeks, and every six months thereafter, although there 
was participant variation in timing and duration of follow up.  
 
Following phlebotomy and lumbar puncture, CSF total WBC, lymphocyte counts, total 
protein, albumin, and blood/plasma albumin were measured from fresh samples. Frozen 
samples were prepared for assays of HIV RNA, neopterin, and NFL: Fresh samples were 
maintained on ice, and, after low-speed centrifugation, cell-free CSF and paired blood 
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plasma aliquots were stored within 2 hours of collection in −70°C to −80°C freezers. 
Previous studies have demonstrated neopterin and NFL to tolerate repeated freeze-thaw 
cycles and long-term storage with minimal compromise in integrity115,116, although both 
conditions were minimized as much as possible throughout the course of this study.  
 
CSF NFL was measured with the NF-light® ELISA kit (UmanDiagnostics AB, Umeå, 
Sweden), a sensitive immunoassay with a lower limit of detection of 50 ng/L 86, and 
reference values for upper limit of normal of 380 ng/L (18–29 years), 560 (30–39years), 
890 (40–59 years), and 1850 (>59 years)86.  CSF NFL assays were singularly performed 
in the Laboratory of Neurochemistry at the University of Gothenburg on previously 
frozen samples.  
 
CSF and plasma albumin were measured by nephelometry (Behring Nephelometer 
Analyzer, Behringwerke AG, Marburg, Germany). QAlb was calculated as the 
CSF/plasma albumin ratio: CSF albumin (mg/l)/plasma albumin (g/l) 87. Upper limits of 
normal were based on previously established values of <6.8 for age <45 years, and <10.2 
for age >45 years 117.  CSF and plasma albumin were measured in local clinical 
laboratories. Given the inherent advantage of being a ratio, QAlb is laboratory- and 
method-independent.  
 
CSF and plasma neopterin was measured in the laboratory of Dr. Fuchs by commercial 
immunoassays (BRAHMS, Berlin, Germany) on previously frozen samples. CSF white 
blood cells, lymphocytes, total protein, and HIV RNA were measured in local 
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laboratories as previously described60 and outlined below. CD4+ and CD8+ lymphocytes 
and white blood cells were measured in fresh, paired CSF and blood/plasma samples 
using flow cytometry. HIV RNA (viral load) was quantified in previously frozen, paired 
cell-free CSF and plasma samples at local laboratories using either the ultrasensitive 
Amplicor HIV Monitor PCR (version 1.5; Roche Molecular Diagnostic Systems, 
Branchburg, NJ), Cobas TaqMan RealTime HIV-1 PCR (version 1 or 2; Hoffmann-La 
Roche, Basel, Switzerland), or the Abbott RealTime HIV-1 PCR assay (Abbot 
Laboratories, Abbot Park, IL, USA). Viral loads below 50 copies/mL were assigned a 
value of 49 copies/mL (1.69 on log10 scale).  
 
Neuropsychological performance was determined through the appraisal of gross and fine 
motor skills, processing speed, executive function, learning, and verbal memory through 
a battery of 11 tests. Performance was summarized as an aggregate total Z score and a 
brief NPZ-4 score (including grooved pegboard, digit symbol, finger tapping, and timed 
gait).  
 
A trained neuro-radiologist interpreted MRI data for exclusion of non-HIV associated 
pathologies and assignment of atrophy and white matter hyperintensity ratings. Brain 
MRI/MRS was obtained at the San Francisco site only. MRS data were processed and 
analyzed with the spectral fitting software SITools, which uses a parametric model of 
known (metabolites) and modeled spectral components (macromolecules) to fit all 
resonances and nonparametric parameters to the baseline. Metabolite disturbances can 
indicate neuropathology, including inflammation and injury. The ratio of the peak area 
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under the curve for the metabolite N-acetylaspartate to the peak area under the curve for 
creatine-containing metabolites (NAA:Cr) is a putative marker of neuronal viability and 
number. We focused spectral acquisition on the parietal grey matter, as we have 




Baseline characteristics were summarized as frequencies for categorical variables and 
median and IQR for continuous variables. Non-parametric, Chi-square, and Fisher's exact 
test were used for group comparisons. Specifically, comparison between independent 
groups was performed with the nonparametric method of Mann Whitney U-test for 
continuous variables, unpaired t-test for normal distribution, and the chi2 test or Fisher's 
exact test for categorical variables; comparison between dependent samples (repeated 
measures of participants pre- and post-cART) was performed with Wilcoxon signed-rank 
test. Analysis of covariance (ANCOVA) was performed to compare QAlb between PHI 
and controls while adjusting for the potential confounders of age and sex.  
  
The mixed-effects model was used to analyze longitudinal change of QAlb post-
transmission, both pre- and post-cART. This model includes both fixed and random 
effects in the same analysis, allowing for variation in the number and time interval of 
participant follow-up visits. Because albumin ratio increases with normal aging, the 
equation was adjusted for baseline age by including it as a fixed-effect covariate in the 
model. To account for a possible non-linear trajectory of QAlb over time, a quadratic term 
(t2) was also included as a fixed-effect covariate along with days post-transmission (t). 
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The model included a personal intercept for each subject as a random effect, allowing 
baseline QAlb to vary for each participant. An interaction term was initially added to 
assess whether the trajectory of QAlb over time depended on the baseline QAlb, but was 
found to be insignificant and thus excluded from the final model. QAlb values were log-
transformed for normal distribution before longitudinal analysis. As transformed results 
were comparable to non-log-transformed analysis, the latter results are reported for 
familiarity of QAlb values. For the equations generated, the final y-intercept was 
calculated as follows: [(parameter estimate of baseline age)*(median age of 
subgroup)]+parameter estimate of subgroup intercept. 
  
Partial correlation coefficients were calculated to determine potential relationships 
between QAlb and other measured parameters, as indicated, while adjusting for effects of 
age. Correlations were computed as a cross-sectional analysis using each participant's 
baseline values, as well as a longitudinal analysis using the intra- and inter-subject 
method of Bland and Altman118,119. Specifically, the intra-subject, or 'within subject', 
method determines the correlation of QAlb and a second variable within a subject over the 
course of the study, thus assessing the longitudinal relationship between the two variables 
while removing variation due to subjects. In other words, it assesses whether an increase 
in the QAlb of an individual subject is associated with a change in the second variable. For 
the inter-subject, or 'between subject', method, each subject's repeated measures over the 
course of the study are averaged for QAlb and the second variable, and a simple regression 
is performed with the weighted means. In other words, this approach assesses whether 
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individuals with elevated QAlb throughout the study also tended to have 
elevated/depressed values of the second variable.  
 
 Statistical analyses employed SPSS 23.0 statistical package (IBM Corp., Armonk, NY). 




Patient recruitment, data collection, and laboratory analysis were performed previously 
by the research groups of Drs. Serena Spudich, Magnus Gisslén, and Richard W. Price in 
their cohort studies evaluating the CNS effects of HIV in PHI. This study of blood brain 
permeability in the context of the data available from these cohorts was designed by 
Elham Rahimy and Serena Spudich.  Statistical analyses were performed by Elham 
Rahimy and confirmed by Fang-Yong Li. Additionally, Fang-Yong Li provided 
invaluable teaching on the more complex statistical analyses such as the mixed-effects 
model. Elham Rahimy also created figures, tables, and drafted the manuscript. All the 
authors assisted in revising the manuscript and approved the final version.  
  
RESULTS 
Study participant characteristics 
 
106 PHI participants fulfilled the inclusion criteria and had available QAlb values. Nine 
participants experienced clinically overt neurological disorders during seroconversion:  
meningitis (n=2), headache with photophobia (n=5), brachial neuritis (n=2), Guillain-
Barre syndrome, facial palsy, and encephalitis.  Total visits ranged from 1 to 13 with a 
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median of 2, and follow-up ranged up to 3572 days with a median of 50 days. The 
majority of participants were infected with subtype B virus 60.  
 
The baseline characteristics of PHI and uninfected control participants are presented in 
Table 1. The median duration of HIV infection in PHI participants was 91 days; plasma 
viral load in PHI was 1.8 log10 greater relative to that in the CSF compartment. As 
compared to the HIV-uninfected participants, the PHI cohort had a higher percentage of 
males, and was younger. As expected, PHI participants had a lower CD4 count, elevated 
CD8 count, and decreased CD4/CD8 ratio. As previously reported, CSF white blood cells 
were elevated in the PHI group, as well as CSF neopterin, a marker of macrophage 
activation. Despite the younger age, PHI participants had elevated NFL and equivalent 
CSF total protein compared to the uninfected group, two parameters that increase with 
normal aging 86,120,121.   
 
Information regarding drug and alcohol use was available for participants from the San 
Francisco site (n=82) only: 33.0% reported recent alcohol abuse, and 49.1% reported 
recent drug use. The most frequently reported drug use were methamphetamine, 
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Table 1. Baseline demographic and clinical characteristics of study participants  
 
Values are expressed as median and IQR (Q1, Q3). 
ARS, acute retroviral syndrome; CSF, cerebrospinal fluid; GOT, Gothenburg, Sweden; NFL, neurofilament 
light chain; SF, San Francisco, USA; WBC, white blood cell count. 
 
Blood brain barrier permeability at baseline 
 
At baseline, age adjusted QAlb was elevated in the PHI cohort compared to controls 
(means 5.9, 95% CI 5.5 to 6.3 in PHI; and 5.0, 95% CI 4.4 to 5.6 in controls; p=0.02). 
Using previously published reference values117, baseline QAlb was above the age-specific 
upper limit of normal (ULN) in 22 PHI participants (21%), referred to as the "high 
baseline QAlb subgroup." The remaining 84 PHI participants with baseline QAlb values 
Primary HIV infection  
(n=106) 
HIV uninfected 
(n=64) p value 
Sex (% male) 94! 82! 0.001!
Age (y) 36 (29, 46)! 43 (34, 50)! 0.003!
Site SF!(n=82)!!GOT!(n=24)! SF!
Days post-HIV transmission 91 (53, 149)! ---! ---!
CD4+ count (cells/µl) 567 (402, 709) 808 (678, 1009) <0.001 
CD8+ count (cells/µl) 954 (714, 1358) 487 (343, 733) <0.001 
CD4/CD8 0.528 (0.391, 0.791) 1.76 (1.32, 2.18) <0.001 
Plasma HIV RNA (log10copies/ml) 4.69  (4.08, 5.34) --- --- 
CSF HIV RNA (log10copies/ml) 2.83  (2.14, 3.51) --- --- 
Plasma:CSF HIV RNA ratio 
(log10copies/ml) 
1.81 (1.33, 2.28) -- -- 
CSF WBC count (cells/mm3) 6 (2, 11) 2 (0, 3) <0.001 
CSF total protein (mg/dl) 41 (31, 51) 41 (31, 54) 0.611 
NFL (pg/ml) 518  (391, 819) 411  (320, 550) <0.001 
CSF neopterin 9.6 (6.8, 20.4) 5.0 (4.1, 6.8) <0.001 
% neurosymptomatic ARS 8.5% (n=9) -- -- 
Total number of visits 2 (1, 3) --- --- 
Duration of follow up (days) 50 (0, 450) --- --- 
(nmol/l) 
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below the ULN are referred to as the "normal baseline QAlb subgroup."  The baseline 
clinical characteristics of these two subgroups are summarized in Table 2.  4/17, or 24%, 
in the high baseline QAlb subgroup had neurosymptomatic seroconversion versus 8/64, or 
13%, in the normal baseline QAlb subgroup, although statistically insignificant. Elevated 
NFL, CSF total protein, CSF neopterin (but not blood neopterin), CD8+ T cell count, and 
a decreased plasma:CSF HIV RNA ratio were found in the high baseline QAlb as 
compared to normal baseline QAlb group.  
 
Table 2: Baseline clinical characteristics of high and normal QAlb subgroups 
 
Values are expressed as median and IQR (Q1, Q3). 
ARS, acute retroviral syndrome; CSF, cerebrospinal fluid; NFL, neurofilament light chain; WBC, white 
blood cell count. 
Subgroup with  
High Baseline QAlb 
(n=22) 
Subgroup with 
Normal Baseline QAlb 
(n=84) 
p value 
Age (y) 36 (29, 45)! 37 (28, 46)! 0.797!
Days post-HIV transmission 85 (60, 125)! 92 (51, 150)! 0.785!
CD4+ count (cells/µl) 596 (484, 681) 550 (389, 730) 0.469 
CD8+ count (cells/µl) 1294 (792, 1620) 915 (706, 1200) 0.023 
CD4/CD8 0.463 (0.321, 0.791) 0.530 (0.391, 0.803) 0.376 
Plasma HIV RNA (log10copies/ml) 4.60 (3.91, 5.39) 4.69 (4.09, 5.32) 0.629 
CSF HIV RNA (log10copies/ml) 3.23 (1.77, 3.87) 2.73 (2.14, 3.43) 0.340 
Plasma:CSF HIV RNA ratio 
(log10copies/ml) 
1.27 (0.464, 2.16) 1.84 (1.50, 2.29) 0.020 
CSF WBC count (cells/mm3) 7 (4, 13) 5 (2, 11) 0.087 
CSF total protein (mg/dl) 59 (52, 74) 37 (28, 42) <0.001 
NFL (pg/ml) 857 (468, 1474) 498 (360, 729) 0.008 
Blood neopterin 18.0 (10.8, 28.9) 14 (9.4, 21.3) 0.183 
CSF neopterin 14.3 (8.4, 32.0) 9.0 (6.5, 17.4) 0.035 
Baseline QAlb  9.18 (7.5, 11.3) 4.66 (3.57, 5.75) <0.001 
% neurosymptomatic ARS 18% (n=4) 6.0% (n=5) --- 
Total number of visits 2 (1, 3) 2 (1,3)  0.617 
Duration of follow up (days) 48 (0, 398) 51 (0, 455) 0.715 
(nmol/l) 
(nmol/l) 
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Statistically significant parameters are bolded.  
 
Longitudinal blood brain barrier permeability in PHI prior to cART 
 
The individual trajectories of each PHI participant's QAlb over the duration of the study 
prior to cART initiation are plotted in Figure 2. A mixed model analysis to evaluate the 
natural history of blood brain barrier integrity in the overall PHI group prior to cART did 
not reveal a significant change in QAlb over time (-0.000436/day, p=0.092).  Figure 3 
compares the trajectories of the high and normal baseline QAlb groups. The high baseline 
group showed a declining trend (-0.00305/day, p=0.011) while the normal baseline group 
initially increased (0.00144/day, p= 0.006) and reached a plateau quickly (quadratic time 
effect p= 0.004). These results indicated the heterogeneous time effect in two subgroups.  
 
Figure 2: Natural history of blood brain barrier integrity pre-cART in total cohort. 
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Figure 3: Natural history of blood brain barrier integrity pre-cART upon cohort stratification. Graphs 
demonstrate individual participant and overall trajectory of QAlb in cART-naive participants upon 
stratification into high and low baseline QAlb subgroups. Dashed gray lines simply indicate upper limit of 
normal for participants aged <45 years (at QAlb=6.5) and those aged >45 years (at QAlb=10.2).  
 
Correlation of blood brain barrier integrity with markers of neuropathogenesis 
 
To further evaluate the implications of elevated QAlb, correlations between QAlb and 
markers of neuronal health were evaluated in pre-cART study intervals (Figure 4). 
Partial correlation coefficients were calculated to correct for the confounding effects of 
age, as QAlb and NFL both directly correlate with age. QAlb demonstrated a strong positive 
correlation with NFL, a marker of active neuronal injury, upon cross-sectional analysis at 
baseline (r=0.497, p<0.001), and longitudinally with both between-participant (r=0.555, 
p<0.001) and within-participant analysis (r=0.523, p=0.001). QAlb inversely correlated 
with NAA:Cr, a cerebral metabolite biomarker of neuronal health, upon cross-sectional 
analysis at baseline (r=-0.352, p=0.015), and longitudinally with between-participant 
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analysis (r=-0.387, p=0.008) but not within-participant analysis (r=0.218, p=0.125). MRS 
was performed at a median 114 days post infection (dpi). QAlb did not correlate with 
composite z-scores (total Z or NPZ4) of neuropsychological testing at baseline nor in 
longitudinal analysis (data not shown).   
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Characteristics of cART-treated study participants  
 
Fifty-eight PHI participants initiated a cART regimen during study follow-up, although 
one participant was excluded for virologic failure (two consecutive plasma samples with 
HIV RNA >50 copies/mL after 6 months of ART). Treatment regimens were 
heterogeneous, consisting of 10 integrase-based, 25 protease-based, and 22 NNRTI-based 
(15 of which were efavirenz-based), with 19 distinct combinations. cART was initiated at 
a median 225 dpi, with 402 days median on-cART follow-up. Table 3 compares the 
cross-sectional laboratory parameters before (last visit before treatment) and after cART 
treatment (last visit of study) in those who initiated cART. There was improvement in 
most parameters after approximately a year of cART: suppression of plasma and CSF 
HIV RNA to the lower limit of PCR detection (p<0.001), increased CD4+ counts 
(p<0.001), decreased WBC count (p<0.001), and decreased blood and CSF neopterin 
(p<0.001). In this comparison, NFL and albumin ratio did not significantly change with 
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Table 3: Pre- and post-treatment characteristics of participants initiating cART 
 
Values are expressed as median and IQR (Q1, Q3). Group comparisons were performed using non-
parametric analysis for related samples.  
CSF, cerebrospinal fluid; NFL, neurofilament light chain; WBC, white blood cell count.  
An=21 paired; Bn=42 paired. 
Statistically significant parameters are bolded.  
 
 
Longitudinal history of blood brain barrier integrity following cART initiation 
 
A mixed model analysis was performed to assess the longitudinal trajectory of QAlb over 
13 months of cART (Figure 5). Three participants were recruited into the cohort already 
on cART (for 29, 27, and 19 days) and thus were included in the linear mixed model 
(n=60) but excluded from Table 3. As cART was initiated at a median of 225 dpi (t=0 on 
Figure 5), this time-point corresponded with the linear portion of Figure 3, where the 
quadratic changes of the normal baseline subgroup are resolving and reaching a set-point. 
Thus, initial analysis was performed with the total cART-treated group rather than 
separating into subgroups of high and normal baseline QAlb. There was no significant 
 ! Last pre-cART visit (n=57)! cART-treated endpoint! p value!
Age (y) 41 (29, 46) --- --- 
Days post-HIV transmission 225 (96, 760) --- --- 
Days prior to ART initiation 19 (3, 85) --- --- 
# follow-up visits --- 2 (1, 6) --- 
Days on cART --- 402 (192, 1060) --- 
CD4+ count (cells/µl) 431 (282, 588) 643 (483, 787) <0.001 
Plasma HIV RNA (log10copies/ml) 4.9 (4.4, 5.3) 1.69 (1.69, 1.69) <0.001 
CSF HIV RNA (log10copies/ml) 3.4 (2.6, 4.0) 1.69 (1.69, 1.69) <0.001 
Plasma:CSF HIV RNA ratio 
(log10copies/ml) 
1.49 (0.71, 2.08) 0.00 (0.00, 0.20) <0.001 
CSF WBC count (cells/mm3) 4 (6, 14) 2 (1, 3) <0.001 
CSF total proteinA 40 (33, 50) 35 (29, 42)  0.001 
NFL (pg/ml)B 640 (515, 965) 670 (453, 1072) 0.911 
QAlb 5.18 (3.92, 6.40) 5.09 (3.87, 6.21) 0.832 
Blood neopterin 18.4 (8.4, 24.9) 7.6 (5.2, 12.9) <0.001 
CSF neopterin 13.9 (7.8, 21.6) 5.2 (4.7, 7.7) <0.001 
(nmol/l) 
(nmol/l) 
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change detected in QAlb over the median >1 year duration of cART treatment (slope=-
0.00369/month, p=0.174). With group stratification, the high baseline subgroup (n=7) 
demonstrated no significant change in QAlb over time (p=0.783). The low baseline 
subgroup (n=53) demonstrated a slope of effectively zero (slope=0.00008/month, 
p=0.004), similar to the pre-cART plateau. 
 
Figure 5: Effects of cART on trajectory of blood brain barrier permeability. Scatterplot shows individual 
participant and overall trajectory of QAlb pre- and post- cART initiation (indicated by dashed red line at 
t=0). Linear mixed model analysis generated the equations shown. Blue line shows trajectory of QAlb pre-





In this study, we analyzed the natural history of BBB permeability during primary HIV 
infection, and the influence of early cART. We showed that the albumin ratio is mildly 
elevated in PHI participants compared to uninfected controls when correcting for age. 
This correction is relevant given that BBB permeability increases with normal aging122, 
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and may explain why previous studies have not reported abnormalities in BBB 
permeability during PHI when compared to controls, given that most early HIV studies 
enroll young patients. That being said, we have previously identified moderate elevation 
of albumin ratio in PHI 50,60, and in chronic HIV participants who are cART-naive and 
neuroasymptomatic60. Similarly, Li et al have reported a strong association between 
matrix metalloproteinases--enzymatic surrogate markers of BBB permeability--and 
neurocognitive status in early HIV102.  
 The novelty of this study is our finding that BBB permeability is undergoing 
dynamic changes early in the course of HIV infection, even within days of transmission. 
Two distinct trajectories were noted for the PHI cohort when stratified by baseline 
albumin ratio. Those with a normal baseline albumin ratio (below the ULN) showed a 
mild initial increase that plateaued within the first 1000 days of infection. Despite the 
initial rise, the QAlb remains well below the ULN. As will be discussed below, it may be 
that there is an element of sub-clinical injury associated with this mild rise.  The 
subgroup with high baseline albumin ratios demonstrated a marked decline in albumin 
ratio within the first 1000 days of infection. Presumably an early rise in albumin ratio 
occurred immediately following infection before participant recruitment, and is resolving 
during the follow up. Notably, the subgroup with higher baseline albumin ratio was 
characterized by a higher percentage of neurosymptomatic seroconversion, elevations in 
CSF markers of axonal injury and immune activation, and a higher CSF-to-plasma HIV 
RNA ratio. These findings suggest that a subgroup of PHI participants is susceptible to 
marked BBB disruption, which persists even beyond 1000 days post infection, and is 
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associated with signs of increased CNS involvement. Factors which predispose 
individuals to one trajectory versus the other warrant further investigation.  
 Previous studies have expounded on the association of albumin ratio with 
biomarkers of CNS inflammation and injury123. We confirm that in PHI albumin ratio 
correlates strongly with the axonal injury marker NFL68, and newly demonstrate that it 
inversely correlates with the metabolic marker of neuronal health, NAA:Cr. NFL is a 
sensitive marker of active neuronal damage, and its levels correlate with the severity of 
this damage 51,124,125. We have previously shown NFL to be the most sensitive neuronal 
biomarker for assessing HIV neurodegeneration, as it can detect subclinical injury in 
neuroasymptomatic individuals, even in the early phase of infection 50,126. As disease 
progresses, it is also associated with overt clinical neurological disease, thus not only 
reflecting structural but functional changes124. Although NFL is not specific for HIV 
neurodegeneration50,51, comorbid neurological conditions were excluded from the study 
onset. Similar to QAlb, NFL was elevated in PHI although below the ULN (<560), 
possibly indicating subclinical damage, which may explain the lack of correlation with 
NPZ-4 testing. In line with this conclusion, we have previously shown a lack of 
correlation between NFL and NPZ-4 during PHI, despite showing moderate elevations 
when compared to uninfected controls 50,68. Similar to the utility of NFL as a biomarker 
of early subclinical injury, MRS has been shown to detect early HIV neuropathogenesis 
prior to conventional MRI changes127.  In a recent study, chronically infected HIV 
subjects with cognitive defects were shown to have reduced glutamate and NAA in 
several brain regions, most pronounced in the parietal grey matter128. Here, we extend 
that finding to the early stage of infection.  
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 Once we demonstrated that BBB permeability was altered in PHI, and associated 
with markers of neuronal pathology, we assessed whether early cART treatment could 
remediate these changes. Surprisingly, the effect of cART on BBB permeability has not 
been intensely evaluated. In an unpublished study, Crozier and colleagues observed the 
gradual diminishment of albumin ratio (median 6.48 to 6.09) in 16 neuroasymptomatic 
participants with chronic HIV infection after 200 days of cART therapy111; thus, although 
BBB integrity improved over time with cART therapy, a return to baseline or near 
baseline function may take years. In contrast, Abdulle and colleagues reported no 
significant reduction in BBB permeability after 2 years of cART treatment in 38 
neuroasymptomatic participants32. Importantly, the median baseline albumin ratio of 
participants in the Crozier study was greater than that of participants in the Abdulle study 
(6.48 vs 4.45), potentially contributing to the discrepancy in cohort response to cART.   
 In our study, cART treatment, initiated at a median of 225 days post infection, 
was effective in suppressing CSF and plasma HIV RNA, suggesting medication 
compliance and effectiveness. Notably, the inflammatory marker neopterin improved to 
below the upper level of normal limits both in the plasma and CSF. Despite this systemic 
(including CNS) suppression of viral replication and inflammation, NFL and albumin 
ratio were unchanged. The pre-cART measurement of albumin ratio is comparable to the 
age-matched uninfected controls, and thus may indicate that the acute changes of albumin 
ratio in the high baseline QAlb subgroup had largely resolved and reached near-baseline 
once cART was initiated at 225 days post infection.  On the other hand, although NFL is 
below the age-specific ULN (<840), it is elevated compared to uninfected controls and 
the baseline PHI cohort, given only a marginal age difference. There is a gradual 
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normalization of NFL following axonal injury which is unlikely to persist for over a 
year129. Thus, this persistently elevated level of NFL may reflect continued subclinical 
injury despite cART treatment and what appears to be a largely normal albumin ratio.  
 Notably, we have previously shown a reduction in NFL in response to cART124. 
However, there are important distinctions between the two studies. Although both cohorts 
demonstrate approximately equal proportion of patients with elevated age-specific NFL 
values (38% in the current study, 40% in the previous), the elevations are much less 
marked in the current study: the patients in the current study demonstrate a lower baseline 
NFL upon cART initiation (640 pg/mL [IQR 515, 965] vs 780 ng/L [IQR 480, 7300]) for 
a slightly older cohort (median 41 vs 38 years). Additionally, the previous study had a 
large proportion of neurologically symptomatic patients (ie, with ADC), whom were 
noted to have the more marked elevations in NFL. Furthermore, the current study uses a 
more sensitive NFL assay, possibly more accurately detecting subtle elevations in NFL 
that remain persistently elevated after cART. Our findings in the current study are 
consistent with a more recent study from the Gisslén/Zetterberg group using the same 
highly sensitive assay86 that demonstrated that the subgroup of HIV-infected individuals 
with normal CSF NFL at baseline exhibited no significant reduction in CSF NFL after 
treatment initiation, and also that in the overall group studied, NFL levels did not 
completely normalize in the setting of long-term cART.  Finally, the current study is 
assessing early stage primary HIV infection, while the previous study was assessing 
chronic HIV infection/AIDS, thus there may be inherent differences between the two 
disease stages (although beyond the scope of this study).  
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 We hypothesize that perhaps (1) the initially altered BBB permeability has 
initiated CNS injury which persists despite resolution of BBB integrity, (2) the 
mechanism of injury is independent of BBB integrity, or (3) BBB permeability is mildly 
elevated and has not fully returned to baseline resulting in persisting neuronal injury. 
Alternatively, it is possible that despite the large sample size, we still have insufficient 
power to detect a significant change in NFL and QAlb after cART. Further studies are 
necessary to elucidate the possible explanation. Notably, a previous study showed 
normalization of the CD4/CD8 ratio during PHI only when cART was initiated within 6 
months of transmission130.  Furthermore, in a cohort of individuals started on treatment 
during acute HIV, CSF NFL was not elevated at baseline nor after 6 and 24 months of 
cART131. The effects of earlier cART intervention on albumin ratio normalization should 
be investigated.  
Limitations 
 
In light of the genetic diversity of HIV, the findings of this study are most representative 
of infection with HIV-1 subtype B, the predominant form in Europe, Australia, and the 
Americas132 and the subject of most in vitro experiments and antiretroviral drug 
experiments133.  
 QAlb is affected by many factors not accounted for in this study, including body 
weight and smoking 122. Comorbidities which are highly prevalent in HIV+ individuals, 
such as cardiovascular disease and diabetes mellitus, are known to influence the integrity 
of the BBB. In this study, cholesterol and other cardiovascular risk factors were not 
routinely screened for, although none of the participants had a known history of clinically 
apparent cardiovascular disease such as coronary artery disease, peripheral vascular 
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disease, or stroke. One participant, in the low baseline group, had a known diagnosis of 
diabetes mellitus type 2. Abuse of substances such as cocaine has been shown to at least 
transiently increase BBB permeability45. As indicated in the results, drug use was highly 
prevalent in this cohort, thus, misreporting of ongoing drug use or long-term effects of 
previous drug use cannot be discounted as confounding factors.  
 Furthermore, given the observational nature of this study, cART regimens were 
heterogeneous which may result in distinct effects on the BBB. The influence of distinct 
regimens is further complicated by the fact that several participants changed cART 
regimens throughout the course of the follow-up period for different reasons (ie, drug 
reactions). Therefore, the sample size we have is too small to support a meaningful 
comparison by therapy.  
 In light of the limitations delineated above, the ideal confirmatory study would 
recruit healthy subjects without confounding factors of BBB status--HBV/HCV negative, 
no previous history of drug or alcohol use, no history of cardiovascular disease or 
cardiovascular risk factors, including hypertension, diabetes, or even obesity. Participants 
would be recruited nationwide via different universities/institutions, and would include a 
greater female population (large enough for further analysis upon sex stratification) and 
larger age distribution (again, large enough for further analysis upon stratification). 
Follow-up would begin from day 1 of HIV transmission and follow-up time would be 
homogeneous for all participants (ie, at baseline, six weeks, and every six months 
thereafter until the last day without any loss to follow-up). Participants would have 
excellent access to health care throughout the observational study, so as to minimize 
interference of confounding health conditions on the different measured CSF and blood 
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parameters.  A large portion of participants would then start an antiretroviral therapy 
regimen within the PHI phase and remain compliant with successful viral suppression. 
With an earlier cART initiation, we may thus be able to better assess the effect of cART 
on the BBB permeability trajectory compared to the cART-naive population. 
Additionally, if cART regimens were more homogeneous among participants, we may be 
able to stratify based on regimen characteristics (ie, CPE) to determine if unique 




Blood brain barrier permeability undergoes a dynamic process early in HIV infection, 
demonstrating acute changes within days. We identified two subgroups of PHI 
participants with different albumin ratio trajectories: one with a presumed acute increase 
and gradual improvement over the course of infection, and a second with a mild initial 
increase. BBB permeability correlated with markers of neuropathogenesis. Initiation of 
cART in the first year of infection did not significantly alter BBB permeability in our 
study. Further investigations should test the effects of earlier cART initiation, especially 
in individuals with signs of early BBB disruption.  
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